| 1 |
NCT03319849 |
Recruiting |
A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2 |
- Macular Telangiectasia Type 2
|
- Combination Product: Renexus®
- Procedure: Sham
|
Interventional |
Phase 3 |
- Neurotech Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Change in Ellipsoid Zone (EZ)
- Central Macular Thickness
- Proportion of Eyes with >35% Increase in EZ Break Area
- (and 3 more...)
|
112 |
All |
21 Years to 80 Years (Adult, Senior) |
NCT03319849 |
NTMT-03-B |
|
February 6, 2018 |
October 16, 2019 |
October 16, 2019 |
October 24, 2017 |
April 17, 2018 |
|
- University of Michigan, Kellogg Eye Center
Ann Arbor, Michigan, United States - Retina Center of New Jersey, LLC
Bloomfield, New Jersey, United States - Scheie Eye Institute
Philadelphia, Pennsylvania, United States - (and 3 more...)
|
| 2 |
NCT03316300 |
Recruiting |
A Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2 |
- Macular Telangiectasia Type 2
|
- Combination Product: Renexus®
- Procedure: Sham
|
Interventional |
Phase 3 |
- Neurotech Pharmaceuticals
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Change in Ellipsoid Zone (EZ)
- Central Macular Thickness
- Proportion of Eyes with >35% Increase in EZ Break Area
- (and 3 more...)
|
112 |
All |
21 Years to 80 Years (Adult, Senior) |
NCT03316300 |
NTMT-03-A |
|
November 24, 2017 |
October 16, 2019 |
October 16, 2019 |
October 20, 2017 |
April 9, 2018 |
|
- Scripps Clinic Carmel Valley Ambulatory Surgery Center
La Jolla, California, United States - Jules Stein Eye Institute / David Geffen School of Medicine
Los Angeles, California, United States - Retina Consultants of Southern Colorado, P.C.
Colorado Springs, Colorado, United States - (and 6 more...)
|
| 3 |
NCT03397004 |
Not yet recruiting |
Doxycycline for Hereditary Hemorrhagic Telangiectasia |
- Hereditary Hemorrhagic Telangiectasia (HHT)
|
- Drug: Doxycycline Hyclate
- Drug: Placebo
|
Interventional |
Phase 2 |
- St. Michael's Hospital, Toronto
- Barrow Neurological Institute
- Duke University
- (and 3 more...)
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- The reduction in epistaxis (nose bleeding) severity over 96 weeks
- Change in epistaxis severity score (ESS)
- Measures related to chronic bleeding by a change from baseline
- (and 3 more...)
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03397004 |
160517448
Award Number W81XWH-17-1-0429 |
HHT |
May 2018 |
December 2020 |
December 2020 |
January 11, 2018 |
April 13, 2018 |
|
|
| 4 |
NCT03227263 |
Recruiting |
BABH Study: Efficacy and Safety of Bevacizumab on Severe Bleedings Associated With Hemorrhagic Hereditary Telangiectasia (HHT). |
- Hemorrhagic Hereditary Telangiectasia (HHT)
|
- Drug: Bevacizumab
- Drug: sodium chloride 0.9%
|
Interventional |
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- number of red blood cell transfusions
- hemoglobin
- epistaxis frequency
- (and 6 more...)
|
24 |
All |
18 Years and older (Adult, Senior) |
NCT03227263 |
69HCL17_0018 |
BABH |
September 28, 2017 |
March 2020 |
March 2020 |
July 24, 2017 |
October 18, 2017 |
|
- Hôpital Femme Mère Enfant
Bron, France
|
| 5 |
NCT01752049 |
Recruiting |
Topical Anti-angiogenic Therapy for Telangiectasia in HHT: Proof of Concept |
- Hereditary Hemorrhagic Telangiectasia
|
- Drug: Topical timolol maleate
- Drug: placebo saline drops
|
Interventional |
Not Applicable |
- St. Michael's Hospital, Toronto
- University of California, San Francisco
- The Hospital for Sick Children
- (and 4 more...)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean reduction in lesion area (compared with baseline measurement) of treated telangiectasia.
- 1. From Tissue: Descriptive changes in histopathology in baseline vs treated lesions, vessel density and distribution of capillaries, arterioles and venules.
- 2. From speckle variance OCT: Changes in lesion area, blood flow velocity and volume flow rates (treated vs baseline/ placebo).
- (and 2 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT01752049 |
BVMC 6207
2U54NS065705-06 |
|
May 2013 |
June 2019 |
June 2019 |
December 18, 2012 |
May 18, 2017 |
|
- St. Michael's Hospital
Toronto, Ontario, Canada
|
| 6 |
NCT03152019 |
Recruiting |
Efficacy and Safety of a 0.1% Tacrolimus Nasal Ointment as a Treatment for Epistaxis in Hemorrhagic Hereditary Telangiectasia (HHT) |
- Hemorrhagic Hereditary Telangiectasia (HHT)
|
- Drug: Protopic® (Tacrolimus) 0.1% ointment
- Drug: Placebo
|
Interventional |
Phase 2 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Percentage of patients experiencing an improvement in their nosebleeds
- adverse events
- number of epistaxis
- (and 7 more...)
|
48 |
All |
18 Years and older (Adult, Senior) |
NCT03152019 |
69HCL16_0705 |
TACRO |
May 22, 2017 |
January 2019 |
January 2019 |
May 12, 2017 |
October 18, 2017 |
|
- Hôpital Femme Mère Enfant
Bron, France
|
| 7 |
NCT01158807 |
Recruiting |
Cerebral Hemorrhage Risk in Hereditary Hemorrhagic Telangiectasia |
- Hereditary Hemorrhagic Telangiectasia
|
|
Observational |
|
- St. Michael's Hospital, Toronto
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Observational Model: Case-Control
- Time Perspective: Other
|
|
1800 |
All |
Child, Adult, Senior |
NCT01158807 |
RDCRN# 6203
1U54NS065705 |
BVMN6203 |
April 2010 |
August 2019 |
August 2019 |
July 8, 2010 |
May 18, 2017 |
|
- David Geffen School of Medicine at University of California, Los Angeles
Los Angeles, California, United States - University of California, San Francisco
San Francisco, California, United States - Yale University
New Haven, Connecticut, United States - (and 13 more...)
|
| 8 |
NCT00230620 |
Recruiting |
Molecular Studies on Hereditary Haemorrhagic Telangiectasia Families |
- Telangiectasia, Hereditary Hemorrhagic
|
|
Observational |
|
- Imperial College London
- British Heart Foundation
|
Other |
- Observational Model: Family-Based
|
|
250 |
All |
Child, Adult, Senior |
NCT00230620 |
IC/CLS1 |
|
December 1998 |
November 2018 |
November 2020 |
October 3, 2005 |
May 29, 2015 |
|
- Imperial College Hammersmith Campus
London, United Kingdom
|
| 9 |
NCT02246491 |
Recruiting |
Cell-Based Approaches For Modeling and Treating Ataxia-Telangiectasia |
- Ataxia-Telangiectasia (A-T)
|
- Other: with gene correction
- Other: without gene correction
|
Interventional |
Not Applicable |
- Sidney Kimmel Comprehensive Cancer Center
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- Number of samples of primary A-T fibroblast samples that can be successfully reprogrammed to iPSCs
- Number of samples of patient A-T fibroblasts that can be reprogrammed to iPSCs with and without gene correction
- Quantification of the cloning efficiency of primary cells haploinsufficient for ATM relative to healthy controls
|
20 |
All |
3 Years to 100 Years (Child, Adult, Senior) |
NCT02246491 |
J1491
IRB00038916 |
|
September 2014 |
September 2017 |
September 2018 |
September 22, 2014 |
March 24, 2016 |
|
- SKCCC at Johns Hopkins
Baltimore, Maryland, United States
|
| 10 |
NCT03321916 |
Recruiting |
MacTel Laser Study |
|
- Device: 577-nm PASCAL laser
|
Interventional |
Not Applicable |
- The Lowy Medical Research Institute Limited
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
- Change from baseline cone density as measured by confocal adaptive optics (AOSLO)
- Change in size of ellipsoid zone break area as measured by spectral domain optical coherence tomography (SD-OCT)
- Development or extension post therapy of areas of deficiency in cones as measured by AOSLO
|
12 |
All |
21 Years to 79 Years (Adult, Senior) |
NCT03321916 |
MacTelLaser1 |
|
October 2017 |
December 2019 |
December 2019 |
October 26, 2017 |
October 26, 2017 |
|
- Medical College of Wisconsin & Froedtert Hospital
Milwaukee, Wisconsin, United States
|
| 11 |
NCT03357978 |
Recruiting |
Susceptibility to Infections, Tumor Risk and Liver Disease in Patients With Ataxia Telangiectasia |
|
- Diagnostic Test: bioelectrical impedance analysis
- Diagnostic Test: blood draw
- Diagnostic Test: transient elastography (FibroScan)
- (and 2 more...)
|
Interventional |
Not Applicable |
- Johann Wolfgang Goethe University Hospital
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Infections in A-T
- Liver disease
- Cancer risk
|
30 |
All |
2 Years to 45 Years (Child, Adult) |
NCT03357978 |
InfectionandLiver_AT2016 |
|
October 1, 2016 |
September 30, 2018 |
September 30, 2019 |
November 30, 2017 |
November 30, 2017 |
|
- Children's Hospital, Allergology, Pneumology and Cystic Fibrosis, Goethe University Frankfurt
Frankfurt, Hessen, Germany
|
| 12 |
NCT02977637 |
Recruiting |
MRA With Feraheme in HHT |
- Hereditary Hemorrhagic Telangiectasia
|
- Procedure: Feraheme MRI/MRA
|
Interventional |
Phase 1 |
- University of California, Los Angeles
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Presence or absence of AVM
- Size of AVM
- Location of AVM
- (and 8 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02977637 |
15-001308 |
|
November 2016 |
November 2017 |
November 2017 |
November 30, 2016 |
March 30, 2017 |
|
- UCLA
Los Angeles, California, United States
|
| 13 |
NCT02287558 |
Recruiting |
Pomalidomide in Hereditary Hemorrhagic Telangiectasia and Transfusion-Dependent Vascular Ectasia: a Phase I Study |
- Hereditary Hemorrhagic Telangiectasia
- Idiopathic Vascular Ectasia
|
|
Interventional |
Phase 1 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Transfusion requirement measure
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT02287558 |
CASE4Z14 |
|
January 27, 2015 |
June 2018 |
December 2018 |
November 10, 2014 |
January 25, 2018 |
|
- Cleveland Clinic
Cleveland, Ohio, United States
|
| 14 |
NCT02963129 |
Not yet recruiting |
Treatment of Nasal Staphylococcus Aureus Colonization in Patients With HHT |
- Hereditary Hemorrhagic Telangiectasia
- Epistaxis
|
- Drug: Mupirocin
- Other: Placebo
|
Interventional |
Phase 3 |
- Hospital Italiano de Buenos Aires
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Nosebleed by sadick scale
- Prevalence of nasal colonization with Staphylococcus in patients with HHT by nasal cultive
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02963129 |
2666 |
|
June 2017 |
June 2017 |
December 2017 |
November 15, 2016 |
November 15, 2016 |
|
- Hospital Italiano de Buenos Aires, Peron 4190
Ciudad Autonoma de Buenos Aires, Capital Federal, Argentina - Hospital Italiano de Buenos Aires, Gascon 450
Buenos Aires, Argentina
|
| 15 |
NCT02936349 |
Recruiting |
Graded TTCE for Post-Embolization PAVM Monitoring |
- Hereditary Hemorrhagic Telangiectasia (HHT)
|
- Other: Transthoracic Contrast Echocardiogram
|
Observational |
|
- University of Pennsylvania
|
Other |
- Observational Model: Other
- Time Perspective: Prospective
|
- Differences between TTCE shunt grade and the number of PAVMs present on most recent chest CT scan.
- Differences between TTCE shunt grade and the size of PAVMs present on most recent
- Correlation between TTCE shunt grade to presence of PAVMs amenable to embolotherapy (feeding artery >2 mm) on most recent chest CT
|
100 |
All |
18 Years to 89 Years (Adult, Senior) |
NCT02936349 |
825381 |
|
October 2016 |
October 2018 |
October 2019 |
October 18, 2016 |
February 16, 2018 |
|
- Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 16 |
NCT02638012 |
Recruiting |
Prospective Pilot Study of Floseal for the Treatment of Anterior Epistaxis in Patients With (HHT) |
- Hereditary Hemorrhagic Telangiectasia (HHT)
- Epistaxis
|
- Drug: Floseal
- Other: Packing
|
Interventional |
Not Applicable |
- St. Michael's Hospital, Toronto
- The Ottawa Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Epistaxis Severity Score (ESS) via a questionnaire before and one month following treatment
- Change in number of nose bleeds during one month period following treatment
- Change in severity rating of nose bleeds during one month period following treatment
- (and 2 more...)
|
10 |
All |
18 Years and older (Adult, Senior) |
NCT02638012 |
15-057 |
|
December 2015 |
December 2018 |
February 2019 |
December 22, 2015 |
April 18, 2018 |
|
- St. Michael's Hospital
Toronto, Ontario, Canada
|
| 17 |
NCT02983253 |
Recruiting |
Immunmodulation in Patients With HHT |
- Hereditary Haemorrhagic Telangiectasia (HHT)
|
|
Observational |
|
- University Hospital, Essen
|
Other |
- Observational Model: Cohort
- Time Perspective: Cross-Sectional
|
- Amounts of leucocytes in patients with HHT
- Differences in distribution of leucocytes in patients with HHT
|
200 |
All |
18 Years and older (Adult, Senior) |
NCT02983253 |
ImmunUHEssen |
|
June 2016 |
September 2018 |
December 2018 |
December 6, 2016 |
December 8, 2016 |
|
- University Hospital Essen
Essen, Germany
|
| 18 |
NCT03472859 |
Recruiting |
Treatment of Dilated Blood Vessels on the Cheeks With a New Yellow Laser and a Traditional Green Laser |
|
- Device: PHOTOLASE
- Device: KTP
|
Interventional |
Not Applicable |
- Tampere University Hospital
- Tampere University of Technology
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- TGS change
- VAS pain measurement
- Amount of treatment-related adverse effects using a 4-point scale.
|
30 |
All |
18 Years and older (Adult, Senior) |
NCT03472859 |
R17111 |
|
October 1, 2017 |
December 2018 |
December 2018 |
March 21, 2018 |
March 21, 2018 |
|
- Epilaser Oy
Lempäälä, Pirkanmaa, Finland
|
| 19 |
NCT02770807 |
Recruiting |
EDS in Ataxia Telangiectasia Patients |
- Nervous System Disease
- Genetic Syndrome
|
- Drug: EDS-EP dose range of ~5-10 mg DSP/infusion
- Drug: EDS-EP dose range of ~14-22 mg DSP/infusion
- Drug: Placebo
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Modified International Cooperative Ataxia Rating Scale (mICARS)
- Clinical Global Impression of Change (CGI-C) key secondary outcome measure
- Clinical Global Impression of Severity (CGI-S) of neurological symptoms of AT
- Vineland Adaptive Behavior Scales (VABS)
|
180 |
All |
6 Years and older (Child, Adult, Senior) |
NCT02770807 |
IEDAT-02-2015 |
ATTeST |
March 2, 2017 |
August 2018 |
March 2019 |
May 12, 2016 |
October 31, 2017 |
|
- UCLA
Los Angeles, California, United States - The Ataxia-Telangiectasia Clinical Center, The Johns Hopkins Hospital
Baltimore, Maryland, United States - Cincinnati Children's Hospital Medical Center
Cincinnati, Ohio, United States - (and 18 more...)
|
| 20 |
NCT02857894 |
Recruiting |
Genetic Factors of Idiopathic Polypoidal Vasculopathies in the ATM Gene (Ataxia Telangiectasia Mutated) |
- Choroidal Neovascularization
|
|
Observational |
|
- Fondation Ophtalmologique Adolphe de Rothschild
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02857894 |
MMT_2015_4 |
ATM |
November 5, 2015 |
May 2018 |
May 2018 |
August 5, 2016 |
March 1, 2018 |
|
- Fondation Ophtalmologique A. de Rotchschild
Paris, France
|
| 21 |
NCT01975103 |
Recruiting |
Endpoint Management Software for Photothermal Stimulation of Macular Diseases |
- Diabetic Macular Edema
- Branch Retinal Vein Occlusion
- Chronic Central Serous Retinopathy
- Macular Telangiectasia
|
- Procedure: Topcon Endpoint Management
|
Interventional |
Phase 2 |
- Federal University of Rio Grande do Sul
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Best corrected visual acuity
- Central macular thickness on OCT
|
20 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT01975103 |
EPM-001 |
EPM |
March 2013 |
April 2018 |
|
November 4, 2013 |
May 4, 2017 |
|
- Instituto de Oftalmologia Lavinsky
Porto Alegre, RS, Brazil
|
| 22 |
NCT02389959 |
Recruiting |
Intranasal Bevacizumab for HHT-Related Epistaxis |
- HHT
- Hereditary Hemorrhagic Telangiectasia
- Epistaxis
- (and 2 more...)
|
- Drug: Bevacizumab
- Drug: Placebo (Saline)
|
Interventional |
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Improvement in Epistaxis Severity Score
- Improvement in Quality of Life
- Reduction in epistaxis-related costs (direct and indirect)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT02389959 |
29501 |
|
August 2014 |
September 2018 |
March 2019 |
March 17, 2015 |
April 27, 2017 |
|
- Stanford University Department of Otolaryngology- Head and Neck Surgery
Stanford, California, United States
|
| 23 |
NCT02458703 |
Not yet recruiting |
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs With and Without Airflow Obstruction |
- Pulmonary Arteriovenous Malformations
- Hereditary Hemorrhagic Telangiectasia
- Asthma
- COPD
|
- Other: Cardiopulmonary exercise test
|
Interventional |
Not Applicable |
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Total body oxygen consumption in mls/min/kg, at peak exercise (VO2 max).
- Breathing reserve
- Ventilatory efficiency
|
60 |
All |
16 Years to 80 Years (Child, Adult, Senior) |
NCT02458703 |
CLS 2015/1
15/LO/0598 |
ExercisePAVM2 |
May 2015 |
May 2018 |
May 2018 |
June 1, 2015 |
June 1, 2015 |
|
|
| 24 |
NCT01793168 |
Recruiting |
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford |
- Rare Disorders
- Undiagnosed Disorders
- Disorders of Unknown Prevalence
- (and 260 more...)
|
|
Observational |
|
- Sanford Health
- National Ataxia Foundation
- International WAGR Syndrome Association
- (and 23 more...)
|
Other |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- To accelerate research into rare disorders by connecting individuals who are interested in research and who have been diagnosed with a rare disorder (or a disorder of unknown prevalence, or who are undiagnosed) with researchers who study rare diseases.
|
20000 |
All |
Child, Adult, Senior |
NCT01793168 |
03-10-014
Hypersomnia Foundation
National Ataxia Foundation
4p- Support Group
CdLS Foundation
Hyperacusis Research Limited
Kabuki Syndrome Network
Kawasaki Disease Foundation
Klippel-Feil Syndrome Freedom
Leiomyosarcoma Direct Research
MSS Support Group
ML4 Foundation
Stickler Involved People
IWSA
Soft Bones
PWN4PWN
aHUS
Klippel-Feil Syndrome Alliance
American MEN Support
Kleine-Levin Syndrome
All Things Kabuki
WSS Foundation
BIVA
ABDA
PROS Foundation (HLH) |
CoRDS |
July 2010 |
December 2100 |
December 2100 |
February 15, 2013 |
October 2, 2017 |
|
- Sanford Health
Sioux Falls, South Dakota, United States
|
| 25 |
NCT01856842 |
Recruiting |
Reperfusion of Pulmonary Arteriovenous Malformations After Embolotherapy |
- Pulmonary Arteriovenous Malformations
|
- Procedure: Angiography and embolotherapy
|
Interventional |
Not Applicable |
- St. Michael's Hospital, Toronto
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Single (Participant)
- Primary Purpose: Treatment
|
- Difference in reperfusion rate
- Fluoroscopy/radiation time
- Contrast volume required
- (and 3 more...)
|
40 |
All |
18 Years and older (Adult, Senior) |
NCT01856842 |
01-ANGIO-12 |
|
April 2013 |
April 2018 |
April 2018 |
May 17, 2013 |
May 18, 2017 |
|
- St. Michael's Hospital
Toronto, Ontario, Canada
|
| 26 |
NCT03423628 |
Recruiting |
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer |
- Recurrent Glioblastoma Multiforme
- Primary Glioblastoma Multiforme
- Brain Neoplasms, Malignant
- Leptomeningeal Disease (LMD)
|
- Radiation: Radiation Therapy
- Drug: AZD1390
|
Interventional |
Phase 1 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Incidence of dose-limiting toxicities (DLTs)
- Incidence of adverse events (AEs) and serious adverse events (SAEs)
- Event free survival (EFS) for Arms A and C only
- (and 7 more...)
|
132 |
All |
18 Years and older (Adult, Senior) |
NCT03423628 |
D6940C00002
2017-002451-28
135803 |
|
April 2, 2018 |
April 5, 2021 |
April 5, 2021 |
February 6, 2018 |
April 24, 2018 |
|
- Research Site
Boston, Massachusetts, United States - Research Site
New York, New York, United States - Research Site
Pittsburgh, Pennsylvania, United States - (and 4 more...)
|
| 27 |
NCT00874783 |
Recruiting |
Development of iPS From Donated Somatic Cells of Patients With Neurological Diseases |
- Neurodegenerative Disorders
|
|
Observational |
|
- Hadassah Medical Organization
|
Other |
- Observational Model: Case-Control
- Time Perspective: Prospective
|
|
120 |
All |
18 Years and older (Adult, Senior) |
NCT00874783 |
0599-08-HMO-CTIL |
|
April 2009 |
December 2025 |
December 2025 |
April 3, 2009 |
November 28, 2017 |
|
- Hadassah Ein Kerem
Jerusalem, Israel
|
| 28 |
NCT02620254 |
Recruiting |
Mast Cell Connect: A Registry for Patients With Mastocytosis |
|
|
Observational |
|
- Blueprint Medicines Corporation
- PatientCrossroads
|
Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Further the understanding of the epidemiology of mastocytosis and its subtypes
|
200 |
All |
Child, Adult, Senior |
NCT02620254 |
Mastocytosis Registry |
|
November 2015 |
December 2020 |
December 2020 |
December 2, 2015 |
September 20, 2017 |
|
- Registry participation is worldwide and not limited to this facility
Cambridge, Massachusetts, United States
|
| 29 |
NCT02000089 |
Recruiting |
The Cancer of the Pancreas Screening-5 CAPS5)Study |
- Pancreas Cancer
- Peutz-Jeghers Syndrome (PJS)
- Gene Mutation
- (and 2 more...)
|
- Drug: Human synthetic secretin
|
Observational |
|
- Johns Hopkins University
- ChiRhoClin, Inc.
|
Other / Industry |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Evaluate pancreatic juice for early cancer markers.
- Compare pancreas juice with pancreas cyst fluid
|
2500 |
All |
18 Years and older (Adult, Senior) |
NCT02000089 |
NA_00087754 |
CAPS5 |
January 2014 |
October 2021 |
December 2023 |
December 3, 2013 |
December 7, 2017 |
|
- Yale University
New Haven, Connecticut, United States - Johns Hopkins Hospital
Baltimore, Maryland, United States - Dana Farber Cancer Center, Harvard University
Boston, Massachusetts, United States - (and 5 more...)
|
Create an RSS feed from your search for:
Download the search results for: